Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Follicular 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

pirtobrutinib 5Lenalidomide 4Rituximab 3Imatinib Mesylate 3ruxolitinib 2ponatinib 2ibrutinib 2Platelet Transfusion 2Brentuximab Vedotin 2Bortezomib 2Bendamustine Hydrochloride 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1vosaroxin 1venetoclax 1nilotinib 1idelalisib 1bosutinib 1acalabrutinib 1Zoledronic Acid 1Vorinostat 1Vincristine 1Tretinoin 1Prednisone 1Plasma Exchange 1Granulocyte-Macrophage Colony-Stimulating Factor 1Exercise 1Doxorubicin 1Dexamethasone 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hematologic Diseases × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡